Shionogi Seiyaku KK header image

Shionogi Seiyaku KK

4507

Equity

ISIN JP3347200002 / Valor 763280

Tokyo Stock Exchange (2024-11-19)
JPY 2,091.50+1.01%

Shionogi Seiyaku KK
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Shionogi Seiyaku KK is a pharmaceutical company focused on drug discovery and the development of innovative healthcare products and services. The company collaborates with a variety of partners to address social issues and healthcare needs, aiming to enhance its corporate value and contribute meaningfully to society. Shionogi's business strategy emphasizes the creation of new medical solutions and the delivery of value to its stakeholders, including patients, healthcare providers, and partners. The company is committed to growth and development, leveraging its strengths in pharmaceutical research and development to bring effective treatments to market.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Revenue Growth

Shionogi Seiyaku KK reported a revenue of 435,081 million yen for the fiscal year ending March 31, 2024, reflecting a 2.0% increase compared to the previous fiscal year. This growth was driven by strong sales performance across various segments.

Operating Profit

The company achieved an operating profit of 153,310 million yen for the fiscal year ending March 31, 2024. This represents a 2.9% increase from the previous year, indicating improved operational efficiency and cost management.

Profit Before Tax

Shionogi Seiyaku KK's profit before tax for the fiscal year ending March 31, 2024, was 198,283 million yen, marking a 10.0% decrease from the previous fiscal year. This decline was primarily due to increased investment in research and development.

Dividends

The company declared an annual dividend of 160.00 yen per share for the fiscal year ending March 31, 2024, up from 135.00 yen per share in the previous year. This increase reflects Shionogi Seiyaku KK's commitment to returning value to its shareholders.

Financial Outlook

For the fiscal year ending March 31, 2025, Shionogi Seiyaku KK forecasts a revenue of 455,000 million yen, representing a 4.6% increase. The company also projects a profit before tax of 160,000 million yen, indicating a 4.4% growth, driven by anticipated market expansion and new product launches.

Summarized from source with an LLMView Source

Key figures

-11.7%1Y
-20.3%3Y
-1.39%5Y

Performance

26.8%1Y
28.1%3Y
28.6%5Y

Volatility

Market cap

12022 M

Market cap (USD)

Daily traded volume (Shares)

1,718,100

Daily traded volume (Shares)

1 day high/low

2110 / 2078

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

ImmunityBio Inc
ImmunityBio Inc ImmunityBio Inc Valor: 110468647
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.79%USD 5.35
Hisamitsu Seiyaku KK
Hisamitsu Seiyaku KK Hisamitsu Seiyaku KK Valor: 761916
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.71%JPY 4,254.00
Waystar Holding Corp
Waystar Holding Corp Waystar Holding Corp Valor: 130358792
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.83%USD 31.23
Elanco Animal Health Inc
Elanco Animal Health Inc Elanco Animal Health Inc Valor: 43127600
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.79%USD 13.45
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.26%CAD 22.55
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.65%USD 25.55
STERIS PLC
STERIS PLC STERIS PLC Valor: 47027903
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.38%USD 217.09
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.26%USD 117.36
Galderma Group Ltd
Galderma Group Ltd Galderma Group Ltd Valor: 133539272
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.89%CHF 85.94
Almirall SA
Almirall SA Almirall SA Valor: 3180354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.43%EUR 8.28